Very light in detail
Sydney, Australia, 2 May 2022: Imugene (ASX: IMU) today announced termination of its
supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA.
Imugene is continuing with its clinical trial to evaluate the safety and efficacy with the use of
Imugene’s HER-Vaxx, a B-cell activating immunotherapy in patients with HER-2 positive
gastric cancer in combination with anti-PD-1 therapy.
Ann: Termination of Supply Agreement, page-4
-
- There are more pages in this discussion • 445 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.7¢ | $2.298M | 47.86M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1925982 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3452098 | 12 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |